ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 79 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $305,203 | -59.1% | 57,477 | -26.6% | 0.00% | -100.0% |
| Q2 2023 | $745,932 | +91.0% | 78,272 | +120.5% | 0.00% | – |
| Q1 2023 | $390,467 | -25.7% | 35,497 | +0.0% | 0.00% | -100.0% |
| Q4 2022 | $525,193 | -21.0% | 35,486 | +1.8% | 0.00% | 0.0% |
| Q3 2022 | $665,000 | +75.9% | 34,853 | +96.5% | 0.00% | – |
| Q2 2022 | $378,000 | +14.2% | 17,741 | +2.9% | 0.00% | – |
| Q1 2022 | $331,000 | -9.6% | 17,239 | -2.3% | 0.00% | – |
| Q4 2021 | $366,000 | -63.9% | 17,643 | -58.5% | 0.00% | – |
| Q3 2021 | $1,015,000 | +153.8% | 42,491 | +190.6% | 0.00% | – |
| Q2 2021 | $400,000 | -17.0% | 14,624 | -12.3% | 0.00% | – |
| Q1 2021 | $482,000 | -30.3% | 16,677 | -32.3% | 0.00% | – |
| Q4 2020 | $692,000 | – | 24,618 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $165,956,000 | 12.78% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $57,330,000 | 6.84% |
| Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $10,874,000 | 3.97% |
| Logos Global Management LP | 1,525,000 | $29,143,000 | 3.58% |
| 1492 Capital Management LLC | 178,320 | $3,408,000 | 2.45% |
| Cormorant Asset Management, LP | 1,000,000 | $19,110,000 | 1.34% |
| MPM BioImpact LLC | 257,185 | $4,915,000 | 1.16% |
| Orbimed Advisors | 2,800,000 | $53,508,000 | 0.99% |
| SECTORAL ASSET MANAGEMENT INC | 220,985 | $4,223,000 | 0.83% |
| Rubric Capital Management LP | 472,047 | $9,021,000 | 0.45% |